Enzolytics, Inc. (OTCMKTS:ENZC) Short Interest Update

Enzolytics, Inc. (OTCMKTS:ENZC) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 677,542 shares, a growth of 324,082.8% from the January 15th total of 209 shares. Based on an average trading volume of 7,284,850 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 7,284,850 shares, the days-to-cover ratio is presently 0.1 days.

Enzolytics Stock Performance

Shares of ENZC opened at $0.00 on Wednesday. Enzolytics has a 12 month low of $0.00 and a 12 month high of $0.00.

About Enzolytics

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.